![GT Biopharma Inc](/common/images/company/N_GTBP.png)
GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cance... GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.23 | -7.84982935154 | 2.93 | 2.93 | 2.69 | 12960 | 2.76316954 | CS |
4 | -0.26 | -8.78378378378 | 2.96 | 3.74 | 2.6 | 54982 | 2.81925737 | CS |
12 | -0.53 | -16.4086687307 | 3.23 | 10.6599 | 2.6 | 1554156 | 7.16356425 | CS |
26 | -4.35 | -61.7021276596 | 7.05 | 10.6599 | 2.6 | 721160 | 7.11884994 | CS |
52 | -5.745 | -68.0284191829 | 8.445 | 10.6599 | 2.6 | 435919 | 7.21910898 | CS |
156 | -368.343 | -99.2723215369 | 371.043 | 371.043 | 2.6 | 294388 | 48.42601675 | CS |
260 | -162.3 | -98.3636363636 | 165 | 591.993 | 2.6 | 329218 | 108.79836878 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.